To Phase III or not to Phase III? | GenomeWeb

In the Pipeline's Derek Lowe talks about the occasional "perverse incentives" in oncology drug development. Lowe references an article from 2007 in the Journal of Clinical Oncology written by an investor, Tony Fiorino, who talks about the motives behind oncology research at large pharmaceutical companies versus small biotech start-ups.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.